Table 1.
The formulas of 15 non-invasive fibrosis indices included in the current study.
| Index | Calculation |
|---|---|
| AAR13 | AST/ALT |
| AARP14 | 1: AAR ≥1 or PLT<150 (×109/L) or else, the score = 0 |
| AARPRI15 | AAR/[PLT (×109/L)/150] |
| API16 | Age (years): <30 = 0; 30–39 = 1; 40–49 = 2; 50–59 = 3; 60–69 = 4; >70 = 5PLT (×109/L): 225 = 0; 200 – 224 = 1; 175 – 199 = 2; 150 – 174 = 3; 125 – 149 = 4; <125 = 5API is the sum of the above (possible value 0–10). |
| APRI17 | {[AST (U/L)/ULN]/PLT (×109/L)} × 100 |
| CDS18 | PLT (×109/L): >340 = 0; 280 – 339 = 1; 220 – 279 = 2; 160 – 219 = 3; 100–159 = 4;40–99 = 5; <40 = 6ALT/AST ratio: >1.7 = 0; 1.2–1.7 = 1; 0.6–1.19 = 2; <0.6 = 3INR: <1.1 = 0; 1.1–1.4 = 1; >1.4 = 2CDS is the sum of the above (possible value 0–11) |
| FIB-4 Index19 | Age (years) × AST/[PLT (109/L) × (ALT)1/2] |
| Fibro-α Score20 | 1.35 + AFP (IU/ml) × 0.009584 + AST/ALT × 0.243–PLT (×109/L) × 0.001624 |
| Fibrosis Index21 | 8–0.01× PLT (×109/L) –albumin (g/dL) |
| Firbro Q22 | [10 × Age (y) × AST (U/L) × INR]/[PLT (×109/L)× ALT (U/L)] |
| GUCI23 | Normalized AST × INR × 100/ PLT (×109/L) |
| King Score24 | Age (years) × AST (U/L) × INR/ PLT (×109/L) |
| P2/MS25 | PLT(×109/L)2/(monocyte fraction × segmented neutrophil fraction) |
| PLASA Score26 | 0.067 × Age (years) + 0.020 × AST(U/L)–0.004 × PLT(×109/L) – 3.028 |
| Pohl Score27 | 1: AAR ≥1 and PLT <150 (×109/L) or else, the score = 0 |
AAR: aspartate aminotransferase to alanine aminotransferase ratio; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PLT: platelet count; AARP: AAR-platelet score; AARPRI: AAR-to-platelet ratio index; API: age-platelet index; APRI: AST to platelet ratio index; ULN: upper limit of normal; CDS: cirrhosis discriminant score; INR: international normalized ratio;FIB-4 Index: fibrosis index based on the four factors; AFP: alpha-fetoprotein; Fibro Q: fibro-quotient; GUCI: Goteburg University Cirrhosis Index; PLASA: platelet-AST-age.